Department of Biomedical Engineering, Widener University, Chester, PA, 19013, USA.
Neonatology Research Laboratory, Department of Pediatrics, The Children's Regional Hospital at Cooper, Cooper Medical School of Rowan University, Suite Dorrance 755, One Cooper Plaza, Camden, NJ, 08103, USA.
Semin Fetal Neonatal Med. 2022 Feb;27(1):101325. doi: 10.1016/j.siny.2022.101325. Epub 2022 Mar 28.
Preterm birth and its common complications are major causes of infant mortality and long-term morbidity. Despite great advances in understanding the pathogenesis of neonatal diseases and improvements in neonatal intensive care, effective therapies for the prevention or treatment for these conditions are still lacking. Stem cell (SC) therapy is rapidly emerging as a novel therapeutic tool for several diseases of the newborn with encouraging pre-clinical results that hold promise for translation to the bedside. The utility of different types of SCs in neonatal diseases is being explored. SC therapeutic efficacy is closely associated with its secretome-conditioned media and SC-derived extracellular vesicles, and a subsequent paracrine action in response to tissue injuries. In the current review, we summarize the pre-clinical and clinical studies of SCs and its secretome in diverse preterm and term birth-related diseases, thereby providing new insights for future therapies in neonatal medicine.
早产及其常见并发症是婴儿死亡和长期发病的主要原因。尽管人们在理解新生儿疾病发病机制方面取得了重大进展,新生儿重症监护也有所改善,但仍缺乏针对这些疾病的有效治疗方法。干细胞(SC)治疗作为一种治疗新生儿多种疾病的新方法迅速兴起,令人鼓舞的临床前研究结果为其转化为床边治疗提供了希望。不同类型的 SC 正在被探索用于治疗新生儿疾病。SC 的治疗效果与其分泌组条件培养基和 SC 衍生的细胞外囊泡密切相关,并通过旁分泌作用对组织损伤做出反应。在本综述中,我们总结了 SC 及其分泌组在各种与早产和足月产相关疾病中的临床前和临床研究,为新生儿医学的未来治疗提供了新的见解。